TrialAutopsy: recently updated stopped trialshttps://trialautopsy.tech/Clinical trials recently updated as terminated, withdrawn or suspended, with automatic and unverified reason labels.en [funding business] A Study to Evaluate the Safety and Efficacy of OPB-101 in Platinum-resistant Ovarian Cancerhttps://clinicaltrials.gov/study/NCT07030907NCT07030907-2026-10-26Mon, 26 Oct 2026 00:00:00 +0000Reason given: “Business decision”. Automatic label: funding business (unverified). Sponsor: Outpace Bio, Inc.. Status: terminated. [other] Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)https://clinicaltrials.gov/study/NCT06694454NCT06694454-2026-10-26Mon, 26 Oct 2026 00:00:00 +0000Reason given: “Placed on voluntary hold to new recruitment pending modification to combination monoclonal antibody treatment.”. Automatic label: other (unverified). Sponsor: National Cancer Institute (NCI). Status: suspended. [funding business] Fixed-dose Combination of an Angiotensin Receptor Blocker and Thiazide Diuretic for Essential Hypertensionhttps://clinicaltrials.gov/study/NCT06608472NCT06608472-2026-10-26Mon, 26 Oct 2026 00:00:00 +0000Reason given: “Strategic change in development priorities.”. Automatic label: funding business (unverified). Sponsor: Eurofarma Laboratorios S.A.. Status: withdrawn. [slow accrual] Testing the Feasibility and Acceptability of Social Media and Digital Therapeutics to Decrease Vaping Behaviorshttps://clinicaltrials.gov/study/NCT05994209NCT05994209-2026-10-26Mon, 26 Oct 2026 00:00:00 +0000Reason given: “Due to low recruitment”. Automatic label: slow accrual (unverified). Sponsor: Washington University School of Medicine. Status: terminated. [safety] Evaluation of Efficacy and Safety of Curalin As Add-On Therapy in Adults With Type 2 Diabetes Mellitushttps://clinicaltrials.gov/study/NCT05631431NCT05631431-2026-10-26Mon, 26 Oct 2026 00:00:00 +0000Reason given: “The study was stopped due to suspicion of a safety issue that was later found to be negligible”. Automatic label: safety (unverified). Sponsor: CuraLife. Status: terminated. [funding business] Study of Formoterol 6 mcg/Fluticasone 125 mcg by Eurofarma Laboratórios S.A. Versus Alenia® 6 mcg/200 mcg in Patients With Asthma (FORASMA)https://clinicaltrials.gov/study/NCT07318350NCT07318350-2026-10-23Fri, 23 Oct 2026 00:00:00 +0000Reason given: “Strategic change in development priorities.”. Automatic label: funding business (unverified). Sponsor: Eurofarma Laboratorios S.A.. Status: withdrawn. [funding business] Efficacy and Safety of NVX-CoV2705https://clinicaltrials.gov/study/NCT07086222NCT07086222-2026-10-23Fri, 23 Oct 2026 00:00:00 +0000Reason given: “The study was terminated early due to low COVID-19 incidence and high population immunity, limiting meaningful vaccine efficacy assessment. The decision was made in consultation with FDA/CBER and was unrelated to safety concerns.”. Automatic label: funding business (unverified). Sponsor: Novavax. Status: terminated. [slow accrual] Presence of Anti-RACH Antibodies and Neurocognitive Disorder in Myasthenic or Alzheimers's Patients.https://clinicaltrials.gov/study/NCT06523296NCT06523296-2026-10-23Fri, 23 Oct 2026 00:00:00 +0000Reason given: “recruitment challenges”. Automatic label: slow accrual (unverified). Sponsor: Centre Hospitalier Universitaire de Nice. Status: terminated. [funding business] A Study to Find a Suitable Dose of ASP4396 in Adults With Solid Tumorshttps://clinicaltrials.gov/study/NCT06364696NCT06364696-2026-10-23Fri, 23 Oct 2026 00:00:00 +0000Reason given: “Company's strategic decision”. Automatic label: funding business (unverified). Sponsor: Astellas Pharma Inc. Status: terminated. [funding business] Diffusion Weighted Magnetic Resonance Imaging and the Optic Nerve Neuropathy.https://clinicaltrials.gov/study/NCT05353413NCT05353413-2026-10-23Fri, 23 Oct 2026 00:00:00 +0000Reason given: “Study terminated prematurely due to lack of funding. Seven patients with optic neuropathies were enrolled; no healthy volunteers were enrolled.”. Automatic label: funding business (unverified). Sponsor: Medical University of Bialystok. Status: terminated. [slow accrual] Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failurehttps://clinicaltrials.gov/study/NCT02897063NCT02897063-2026-10-23Fri, 23 Oct 2026 00:00:00 +0000Reason given: “enrollment goal was not met.”. Automatic label: slow accrual (unverified). Sponsor: Vanderbilt University Medical Center. Status: terminated. [slow accrual] Post Intensive Care Unit Atrial Fibrillationhttps://clinicaltrials.gov/study/NCT05860894NCT05860894-2026-10-22Thu, 22 Oct 2026 00:00:00 +0000Reason given: “Insufficient recruitment”. Automatic label: slow accrual (unverified). Sponsor: Centre Hospitalier Universitaire de Besancon. Status: terminated. [futility] A Study of CYP-001 in Combination With Corticosteroids in Adults With High-risk aGvHDhttps://clinicaltrials.gov/study/NCT05643638NCT05643638-2026-10-22Thu, 22 Oct 2026 00:00:00 +0000Reason given: “Cynata Therapeutics has taken the decision to discontinue the study following the Primary Evaluation period analysis. The results did not demonstrate the anticipated clinical benefit of CYP-001 in combination with corticosteroids in HR-aGVHD.”. Automatic label: futility (unverified). Sponsor: Cynata Therapeutics Limited. Status: terminated. [slow accrual] Improve Muscle Weakness in Patient With COPDhttps://clinicaltrials.gov/study/NCT07649850NCT07649850-2026-10-21Wed, 21 Oct 2026 00:00:00 +0000Reason given: “no participant enrolled”. Automatic label: slow accrual (unverified). Sponsor: Al-Zaytoonah University of Jordan. Status: withdrawn. [funding business] Real-time Symptom Monitoring Using ePROs to Prevent Adverse Events During Care Transitionshttps://clinicaltrials.gov/study/NCT05282654NCT05282654-2026-10-21Wed, 21 Oct 2026 00:00:00 +0000Reason given: “Grant Terminated by Sponsor”. Automatic label: funding business (unverified). Sponsor: Brigham and Women's Hospital. Status: terminated. [futility] Efficacy and Safety Extension Study of Oral Edaravone Administered in Subjects With ALShttps://clinicaltrials.gov/study/NCT05151471NCT05151471-2026-10-21Wed, 21 Oct 2026 00:00:00 +0000Reason given: “Futility Analysis of parent study MT-1186-A02 was met.”. Automatic label: futility (unverified). Sponsor: Shionogi. Status: terminated. [funding business] Efficacy and Pharmacogenomics of Cladribine Based Salvage Chemotherapy in Patients With Relapse/Refractory and Secondary Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)https://clinicaltrials.gov/study/NCT03150004NCT03150004-2026-10-21Wed, 21 Oct 2026 00:00:00 +0000Reason given: “No longer have funding support to complete the pharmacogenetics component.”. Automatic label: funding business (unverified). Sponsor: Medical College of Wisconsin. Status: terminated. [logistics pi] Validation of Insulin Dose Prediction Model Based on Artificial Intelligence Algorithmhttps://clinicaltrials.gov/study/NCT07066891NCT07066891-2026-10-20Tue, 20 Oct 2026 00:00:00 +0000Reason given: “Recruitment was stopped early because hospital length-of-stay constraints limited protocol delivery. The PI's decision also took account of the available non-inferiority results.”. Automatic label: logistics pi (unverified). Sponsor: Sun Yat-sen University. Status: terminated. [funding business] Biologically Guided Radiation Therapy (BgRT) and Stereotactic Body Radiation Therapy (SBRT) to Tyrosine Kinase Inhibitor in Oligoprogressive Oncogenic Positive Non-Small Cell Lung Carcinomahttps://clinicaltrials.gov/study/NCT06014827NCT06014827-2026-10-20Tue, 20 Oct 2026 00:00:00 +0000Reason given: “Budget Issue”. Automatic label: funding business (unverified). Sponsor: City of Hope Medical Center. Status: suspended. [slow accrual] Observational Small Intestine and Blood Fingerprint (SmIle) Study in Parkinson's Diseasehttps://clinicaltrials.gov/study/NCT06003608NCT06003608-2026-10-20Tue, 20 Oct 2026 00:00:00 +0000Reason given: “Study recruitment phase exceeded the time allotted”. Automatic label: slow accrual (unverified). Sponsor: Nimble Science Ltd.. Status: terminated. [funding business] A Study to Evaluate INCB099280 in Participants With Advanced Cutaneous Squamous Cell Carcinomahttps://clinicaltrials.gov/study/NCT05888844NCT05888844-2026-10-20Tue, 20 Oct 2026 00:00:00 +0000Reason given: “This was a strategic business decision. There were no safety concerns contributing to this decision.”. Automatic label: funding business (unverified). Sponsor: Incyte Corporation. Status: terminated. [logistics pi] Gastric US in ICU Patienthttps://clinicaltrials.gov/study/NCT05526105NCT05526105-2026-10-20Tue, 20 Oct 2026 00:00:00 +0000Reason given: “Not enough resources (time and manpower) to run study.”. Automatic label: logistics pi (unverified). Sponsor: Dartmouth-Hitchcock Medical Center. Status: withdrawn. [futility] Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cells for Heart Diseasehttps://clinicaltrials.gov/study/NCT05147766NCT05147766-2026-10-20Tue, 20 Oct 2026 00:00:00 +0000Reason given: “Inadequate treatment response observed in preliminary data did not justify enrolling further study participants”. Automatic label: futility (unverified). Sponsor: The Foundation for Orthopaedics and Regenerative Medicine. Status: terminated. [funding business] Anti-VEGF Therapy for Acute Thyroid Eye Diseasehttps://clinicaltrials.gov/study/NCT04311606NCT04311606-2026-10-20Tue, 20 Oct 2026 00:00:00 +0000Reason given: “Funding prematurely ended”. Automatic label: funding business (unverified). Sponsor: Massachusetts Eye and Ear Infirmary. Status: terminated. [slow accrual] Evaluation of Structural and Functional Integrity of the Rotator Cuff After Total Shoulder Arthroplastyhttps://clinicaltrials.gov/study/NCT03921944NCT03921944-2026-10-20Tue, 20 Oct 2026 00:00:00 +0000Reason given: “low enrollment”. Automatic label: slow accrual (unverified). Sponsor: Milton S. Hershey Medical Center. Status: terminated. [futility] Phase II Trial of Nivolumab Plus Ipilimumab in Patients With Renal Medullary Carcinomahttps://clinicaltrials.gov/study/NCT03274258NCT03274258-2026-10-20Tue, 20 Oct 2026 00:00:00 +0000Reason given: “The study met its prespecified futility criteria during the prespecified interim futility analysis after enrolling the first cohort of 10 patients.”. Automatic label: futility (unverified). Sponsor: M.D. Anderson Cancer Center. Status: terminated. [manufacturing supply] Atezolizumab, Guadecitabine, and CDX-1401 Vaccine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancerhttps://clinicaltrials.gov/study/NCT03206047NCT03206047-2026-10-20Tue, 20 Oct 2026 00:00:00 +0000Reason given: “The study was terminated due to a shortage of the drug supply.”. Automatic label: manufacturing supply (unverified). Sponsor: National Cancer Institute (NCI). Status: terminated. [slow accrual] Prophylactic Transfusion In Pregnant in Women With Sickle Cell Diseasehttps://clinicaltrials.gov/study/NCT06979492NCT06979492-2026-10-19Mon, 19 Oct 2026 00:00:00 +0000Reason given: “The study was withdrawn due to no enrollment”. Automatic label: slow accrual (unverified). Sponsor: Emory University. Status: withdrawn. [funding business] IBIS Megastudy- Pilothttps://clinicaltrials.gov/study/NCT06785103NCT06785103-2026-10-19Mon, 19 Oct 2026 00:00:00 +0000Reason given: “On 5/1/25, the US NIH issued Notice: NOT-OD-25-104, which prohibited foreign subawards from being nested under a parent grant. Our pilot trial was scheduled for renewal on 8/1/25, and the NOA was delayed. Without funding, we had to halt the trial.”. Automatic label: funding business (unverified). Sponsor: University of California, San Francisco. Status: terminated. [funding business] A Preliminary Study on the Efficacy of Danggui Shaoyao San and Cuscuta Chinensis in Patients With Primary Dysmenorrheahttps://clinicaltrials.gov/study/NCT06730282NCT06730282-2026-10-19Mon, 19 Oct 2026 00:00:00 +0000Reason given: “The study was stopped early before reaching the planned enrollment of 200 participants because the allocated research budget was exhausted and additional study medication could not be funded. Enrollment will not resume.”. Automatic label: funding business (unverified). Sponsor: Taichung Tzu Chi Hospital. Status: terminated. [funding business] 3rd Generation Resorbable Magnesium Scaffolds vs Biodegradable Polymer Stents in NSTE/ACShttps://clinicaltrials.gov/study/NCT06409117NCT06409117-2026-10-19Mon, 19 Oct 2026 00:00:00 +0000Reason given: “No funding”. Automatic label: funding business (unverified). Sponsor: Konstantinos Toutouzas. Status: withdrawn. [funding business] Integrated Clinical Decision Support for Empiric Antibiotic Selection in Sepsishttps://clinicaltrials.gov/study/NCT06103500NCT06103500-2026-10-19Mon, 19 Oct 2026 00:00:00 +0000Reason given: “Funding.”. Automatic label: funding business (unverified). Sponsor: Ottawa Hospital Research Institute. Status: terminated. [safety] Nivolumab and BMS986205 in Treating Patients With Stage II-IV Squamous Cell Cancer of the Head and Neckhttps://clinicaltrials.gov/study/NCT03854032NCT03854032-2026-10-19Mon, 19 Oct 2026 00:00:00 +0000Reason given: “Study was terminated early due to toxicity concerns by the Sponsor.”. Automatic label: safety (unverified). Sponsor: Thomas Jefferson University. Status: terminated. [regulatory] Efficacy and Safety of XH02 for the Treatment of Hypoparathyroidismhttps://clinicaltrials.gov/study/NCT07197450NCT07197450-2026-10-16Fri, 16 Oct 2026 00:00:00 +0000Reason given: “Enrollment temporarily suspended in accordance with a newly implemented regulation, State Council Decree No. 818, on clinical research and clinical translation of new biomedical technologies; pending review and approval.”. Automatic label: regulatory (unverified). Sponsor: Peking Union Medical College Hospital. Status: suspended. [manufacturing supply] Revive Toric RWE Studyhttps://clinicaltrials.gov/study/NCT06785194NCT06785194-2026-10-16Fri, 16 Oct 2026 00:00:00 +0000Reason given: “Lens manufacturing has been postponed”. Automatic label: manufacturing supply (unverified). Sponsor: Bausch & Lomb Incorporated. Status: withdrawn. [funding business] MILC: A Comprehensive Mobile Application That Addresses the Breastfeeding Challenges of Low-income Hispanic Mothershttps://clinicaltrials.gov/study/NCT06520696NCT06520696-2026-10-16Fri, 16 Oct 2026 00:00:00 +0000Reason given: “Lapse in SBIR reauthorization and lack of funding”. Automatic label: funding business (unverified). Sponsor: Benten Technologies, Inc.. Status: withdrawn. [slow accrual] Belumosudil and Rituximab for Primary Treatment of Chronic Graft-Versus-Host-Diseasehttps://clinicaltrials.gov/study/NCT06046248NCT06046248-2026-10-16Fri, 16 Oct 2026 00:00:00 +0000Reason given: “Lack of funding and slow accrual”. Automatic label: slow accrual (unverified). Sponsor: Northside Hospital, Inc.. Status: suspended. [manufacturing supply] Non-endoscopic EC Screening Program in Northern Iranhttps://clinicaltrials.gov/study/NCT02311712NCT02311712-2026-10-16Fri, 16 Oct 2026 00:00:00 +0000Reason given: “Waiting to receive capsule sponge device from the manufacturer.”. Automatic label: manufacturing supply (unverified). Sponsor: Tehran University of Medical Sciences. Status: suspended. [slow accrual] SBRT Plus Systemic Therapy vs Systemic Therapy Alone in BCLC C Hepatocellular Carcinomahttps://clinicaltrials.gov/study/NCT07274774NCT07274774-2026-10-15Thu, 15 Oct 2026 00:00:00 +0000Reason given: “Difficult to recruit patients”. Automatic label: slow accrual (unverified). Sponsor: Shandong Cancer Hospital and Institute. Status: suspended. [safety] Study of Ianalumab in Adults With Primary Immune Thrombocytopenia (ITP) and Warm-antibody Autoimmune Hemolytic Anemia (wAIHA) Who Have Previously Benefited From Ianalumabhttps://clinicaltrials.gov/study/NCT07039422NCT07039422-2026-10-15Thu, 15 Oct 2026 00:00:00 +0000Reason given: “The study was discontinued due to evolving scientific \& feasibility considerations that could adversely affect recruitment, thereby reducing the likelihood of generating a sufficiently robust dataset to support reliable efficacy \& safety conclusions.”. Automatic label: safety (unverified). Sponsor: Novartis Pharmaceuticals. Status: withdrawn. [other] NHLBI and Cook Trans-Atrial Intra-Pericardial Tricuspid Annuloplasty (TRAIPTA) Early Feasibility Studyhttps://clinicaltrials.gov/study/NCT06479824NCT06479824-2026-10-15Thu, 15 Oct 2026 00:00:00 +0000Reason given: “Enrollment has been put on hold by the sponsor to allow for further engineering evaluation and performance review of the investigational device, as well as reassessment of the underlying device reliability assumptions.”. Automatic label: other (unverified). Sponsor: National Heart, Lung, and Blood Institute (NHLBI). Status: suspended. [funding business] The ENERGY Study: Evaluation of Safety and Tolerability of INZ-701 in Infants With ENPP1 Deficiency or ABCC6 Deficiencyhttps://clinicaltrials.gov/study/NCT05734196NCT05734196-2026-10-15Thu, 15 Oct 2026 00:00:00 +0000Reason given: “The study was terminated by the sponsor prior to planned completion based on a review of the data across indications and overall program considerations. Study termination was not related to participant safety.”. Automatic label: funding business (unverified). Sponsor: Inozyme Pharma. Status: terminated. [slow accrual] Safety and Efficacy of Desensitization Therapy in Sensitized Participants Awaiting Heart Transplantationhttps://clinicaltrials.gov/study/NCT01769443NCT01769443-2026-10-15Thu, 15 Oct 2026 00:00:00 +0000Reason given: “Inability to enroll within funding period”. Automatic label: slow accrual (unverified). Sponsor: National Institute of Allergy and Infectious Diseases (NIAID). Status: terminated. [slow accrual] Evaluation of the Biomechanics of Crowding and the Energetic Cost of Endurance Runners Unilateral Transtibial Amputees.https://clinicaltrials.gov/study/NCT06948695NCT06948695-2026-10-14Wed, 14 Oct 2026 00:00:00 +0000Reason given: “Difficulties in enrolling patients”. Automatic label: slow accrual (unverified). Sponsor: Centre Hospitalier Universitaire de Saint Etienne. Status: terminated. [funding business] A Study to Test Different Doses of BI 765049 Alone and in Combination With Ezabenlimab in Asian People With Advanced Cancer (Solid Tumours) Positive for B7-H6https://clinicaltrials.gov/study/NCT06091930NCT06091930-2026-10-14Wed, 14 Oct 2026 00:00:00 +0000Reason given: “Sponsor decision”. Automatic label: funding business (unverified). Sponsor: Boehringer Ingelheim. Status: terminated. [slow accrual] Adjunctive Intravenous Ascorbic Acid for Advanced Non-Small Cell Lung Cancerhttps://clinicaltrials.gov/study/NCT05849129NCT05849129-2026-10-14Wed, 14 Oct 2026 00:00:00 +0000Reason given: “Insufficient recruitment”. Automatic label: slow accrual (unverified). Sponsor: The Canadian College of Naturopathic Medicine. Status: terminated. [slow accrual] Single Agent ONC201 in Recurrent or Metastatic Endometrial Cancerhttps://clinicaltrials.gov/study/NCT03099499NCT03099499-2026-10-14Wed, 14 Oct 2026 00:00:00 +0000Reason given: “Slow accrual”. Automatic label: slow accrual (unverified). Sponsor: Fox Chase Cancer Center. Status: terminated. [slow accrual] Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancerhttps://clinicaltrials.gov/study/NCT01810913NCT01810913-2026-10-14Wed, 14 Oct 2026 00:00:00 +0000Reason given: “Other - Assessing accrual feasibility”. Automatic label: slow accrual (unverified). Sponsor: National Cancer Institute (NCI). Status: suspended. [funding business] A Study of Weekly Oral Dose of Ecnoglutide (VRB-101) for Weight Maintenance in Participants Who Have Obesity or Overweight With Weight-Related Comorbiditieshttps://clinicaltrials.gov/study/NCT07553299NCT07553299-2026-10-13Tue, 13 Oct 2026 00:00:00 +0000Reason given: “The Study Sponsor made a business decision not to continue the study. The decision was not based on safety findings.”. Automatic label: funding business (unverified). Sponsor: Verdiva Bio Dev Limited. Status: terminated. [slow accrual] Using a Decision-making System to Support the Management of Fever and Acute Pain in Childrenhttps://clinicaltrials.gov/study/NCT07344090NCT07344090-2026-10-13Tue, 13 Oct 2026 00:00:00 +0000Reason given: “Failure to reach the target sample size”. Automatic label: slow accrual (unverified). Sponsor: Qwince Innovation S.r.l.. Status: terminated.